Cargando…

Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors

INTRODUCTION: AZD4877 is a potent Eg5 inhibitor that has been shown to have an acceptable tolerability profile in a Phase I study of Western patients with solid tumors. This study was conducted to evaluate the safety, pharmacokinetic (PK) profile, maximum tolerated dose (MTD) and efficacy of AZD4877...

Descripción completa

Detalles Bibliográficos
Autores principales:	Esaki, Taito, Seto, Takashi, Ariyama, Hiroshi, Arita, Shuji, Fujimoto, Chinatsu, Tsukasa, Koichiro, Kometani, Takuro, Nosaki, Kaname, Hirai, Fumihiko, Yagawa, Katsuro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Inc 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130141/ https://www.ncbi.nlm.nih.gov/pubmed/21765863 http://dx.doi.org/10.1111/j.1753-5174.2011.00034.x

Ejemplares similares

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors
por: Tamura, Kenji, et al.
Publicado: (2016)

Burden on Oncologists When Communicating the Discontinuation of Anticancer Treatment
por: Otani, Hiroyuki, et al.
Publicado: (2011)

Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia
por: Genovese, Giulio, et al.
Publicado: (2016)

The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer
por: Nosaki, Kaname, et al.
Publicado: (2015)

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
por: Shimizu, Toshio, et al.
Publicado: (2016)

A typical carcinoid tumor of the lung presenting with pure persistent ground-glass opacity on high-resolution computed tomography: a case report
por: Yamaguchi, Masafumi, et al.
Publicado: (2017)

Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study
por: Fujiwara, Yutaka, et al.
Publicado: (2018)

Phase I dose‐escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors
por: Esaki, Taito, et al.
Publicado: (2019)

Uncommon features of surgically resected ALK-positive cavitary lung adenocarcinoma: a case report
por: Takamori, Shinkichi, et al.
Publicado: (2017)

A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy
por: Kumagai, Hozumi, et al.
Publicado: (2018)

Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours
por: Yonemori, Kan, et al.
Publicado: (2016)

Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4‐ALK fusion gene
por: Kometani, Takuro, et al.
Publicado: (2018)

Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594, following inhalation in healthy Japanese volunteers
por: Prothon, Susanne, et al.
Publicado: (2019)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
por: Naing, A, et al.
Publicado: (2012)

Evaluation of the Pharmacokinetic Interaction between Lesogaberan (AZD3355) and Esomeprazole in Healthy Subjects
por: Niazi, Mohammad, et al.
Publicado: (2012)

Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects
por: Knöchel, Jane, et al.
Publicado: (2021)

Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study
por: Shimokawa, Mototsugu, et al.
Publicado: (2020)

Epithelial‐mesenchymal transition is activated in CD44‐positive malignant ascites tumor cells of gastrointestinal cancer
por: Nakano, Michitaka, et al.
Publicado: (2018)

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer
por: Appels, N M G M, et al.
Publicado: (2008)

Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
por: Någård, Mats, et al.
Publicado: (2020)

Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study
por: Saka, Hideo, et al.
Publicado: (2017)

Computational performance of Free Mesh Method applied to continuum mechanics problems
por: YAGAWA, Genki
Publicado: (2011)

Free Mesh Method: fundamental conception, algorithms and accuracy study
por: YAGAWA, Genki
Publicado: (2011)

Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β(2)-adrenoreceptor agonist (uLABA)
por: Bjermer, Leif, et al.
Publicado: (2015)

Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Velsecorat (AZD7594) Following Inhalation in Healthy Volunteers
por: Prothon, Susanne, et al.
Publicado: (2022)

Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non‐small‐cell lung cancer
por: Otsubo, Kohei, et al.
Publicado: (2017)

Metastatic esophageal cancer presenting as shock by injury of vagus nerve mimicking baroreceptor reflex: A case report
por: Tsuchihashi, Kenji, et al.
Publicado: (2017)

Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients
por: Haratake, Naoki, et al.
Publicado: (2019)

Pharmacokinetic Profile of Lesogaberan (AZD3355) in Healthy Subjects: A Novel GABA(B)-Receptor Agonist Reflux Inhibitor
por: Niazi, Mohammad, et al.
Publicado: (2012)

Determination and pharmacokinetic study of AZD‐3759 in rat plasma by ultra performance liquid chromatography with triple quadrupole mass spectrometer
por: Wu, Qingjun, et al.
Publicado: (2018)

Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability
por: Ericsson, Hans, et al.
Publicado: (2019)

International Conference on Computational Engineering Science
por: Atluri, S, et al.
Publicado: (1988)

Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy
por: Kusaba, Hitoshi, et al.
Publicado: (2016)

Metastatic esophageal carcinosarcoma comprising neuroendocrine carcinoma, squamous cell carcinoma, and sarcoma: A case report
por: Tsuchihashi, Kenji, et al.
Publicado: (2018)

A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK
por: Dean, Emma, et al.
Publicado: (2018)

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers
por: Cullberg, Marie, et al.
Publicado: (2018)

Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV‐2 Infection
por: Bender Ignacio, Rachel A., et al.
Publicado: (2022)

Exploring the benefits of in-diet versus repeated oral dosing of saracatinib (AZD0530) in chronic studies: insights into pharmacokinetics and animal welfare
por: Vasanthi, Suraj S., et al.
Publicado: (2023)

International Conference on Computational Mechanics
por: Yagawa, Genki, et al.
Publicado: (1986)

AZD-1222: Guillain-Barre syndrome
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mrg0ks52muj5kh5e5limvv5ena